Company: IXHL
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001213900-25-043682
Chunk: 27

Company: Incannex Healthcare Inc.
Filing Date: 2025-05-15
Form: 10-Q
Item: Part I, Item 1
Chunk 27
---
 Basic and diluted loss per share – (dollars per share) 
     (0.84) 
     (0.76)
  
    The loss and weighted average number of common stock used in the calculation of basic loss per share is as follows: 

    Total comprehensive loss for the year (in thousands) 
     (15,282) 
     (11,998)
  
    - Weighted average number of common stock (number) 
     18,238,863  
     15,873,113 

    For the three months ended March 31, 

    2025
$  
    2024
$ 
  
    Basic and diluted loss per share – (dollars per share) 
     (0.20) 
     (0.38)
  
    The loss and weighted average number of common stock used in the calculation of basic loss per share is as follows: 

    Total comprehensive loss for the year (in thousands) 
     (3,968) 
     (6,031)
  
    - Weighted average number of common stock (number) 
     19,632,539  
     15,873,113 

The Company notes that the diluted loss per share
is the same as basic loss per share.

Note 16 – Related Party Transactions

Transactions between related parties are on commercial
terms and conditions, no more favorable than those available to other parties unless otherwise stated.

There were no amounts payable to any related parties as of March 31,
2025 and June 30, 2024.

19

Item 2. Management’s Discussion and Analysis of Financial
Condition and Results of Operations 

The following discussion should be read in conjunction
with the unaudited condensed consolidated financial statements and notes thereto included elsewhere in this Quarterly Report on Form 10-Q
(this “Quarterly Report”). This Quarterly Report contains forward-looking statements. This discussion and analysis contain
forward looking statements and involves numerous risks and uncertainties, including, but not limited to, those described in the “Risk
Factors” section in our Annual Report on Form 10-K, as filed with the SEC on September 30, 2024 (the “2024 Annual Report”)
and this Quarterly Report. We caution the reader not to place undue reliance on these forward-looking statements, which reflect management’s
analysis only as of the date of this Quarterly Report. We undertake no obligation to update forward-looking